Affiliation:
1. Divisione Urologica - Ospedale Civile di Mantova.
Abstract
15 patients with primitive carcinoma in situ of the bladder were administered 50 mg/week of Epirubicin; 14 responded to this control therapy with negative urinary cytology and biopsies within an average of 25.6 months. After an average follow up of 47.7 months, 8 out of the 15 patients are still in a state of complete remission, 1 has a recurrent grade 3 carcinoma, 5 are in progression (3 T1 and 2 T2) and 1 has a grade 2 Ta recurrence. 3 patients died from the disease.